Orchid Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Revenue from operations rose marginally to Rs 237.61 crore in Q4 FY26 as against Rs 237.48 crore posted in the same period last year.

Profit before exceptional items and tax stood at Rs 22.25 crore, up 16.55% from Rs 19.09 crore reported in Q4 FY25. The company reported exceptional items of Rs 0.54 crore during the quarter.

For the full financial year FY26, the company reported a 79.37% decline in consolidated net profit to Rs 20.55 crore, while revenue from operations fell 11.99% year-on-year to Rs 811.33 crore compared with FY25.

Orchid Pharma is a Chennai-based pharmaceutical company engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals, with exports to over 40 countries.

Powered by Capital Market - Live News

Net profit of Orchid Pharma rose 6.68% to Rs 23.78 crore in the quarter ended March 2026 as against Rs 22.29 crore during the previous quarter ended March 2025. Sales rose 0.05% to Rs 237.61 crore in the quarter ended March 2026 as against Rs 237.48 crore during the previous quarter ended March 2025.

For the full year,net profit declined 79.38% to Rs 20.55 crore in the year ended March 2026 as against Rs 99.66 crore during the previous year ended March 2025. Sales declined 12.00% to Rs 811.33 crore in the year ended March 2026 as against Rs 921.93 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Net loss of Orchid Pharma reported to Rs 12.61 crore in the quarter ended December 2025 as against net profit of Rs 20.78 crore during the previous quarter ended December 2024. Sales declined 4.63% to Rs 207.27 crore in the quarter ended December 2025 as against Rs 217.34 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News